A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
NCT ID: NCT00351325
Last Updated: 2009-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
45 participants
INTERVENTIONAL
2007-09-30
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers
NCT00792558
Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors
NCT01986218
A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies
NCT00207025
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
NCT01351350
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
dose escalation
BMS-663513
mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BMS-663513
mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy of ≥ 6 months
* Solid tumor malignancy for which paclitaxel and carboplatin are appropriate
Exclusion Criteria
* Any concurrent cancer
* History of autoimmune diseases
* Symptomatic bowel obstruction
* Continued use of steroids
* Symptomatic brain metastases
* Current nerve damage in fingers/toes
* Positive for HIV, hepatitis B/C
* White blood cells \< 3,000
* Hemoglobin \< 9
* Platelets \< 100,000
* ALT/AST and/or alkaline phosphatase \>= 2.5 x ULN
* Creatine \> 1.5
* Prior BMS-663513
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Of Pennsylvania Medical Center
Philadelphia, Pennsylvania, United States
Magee-Womens Hospital Of Upmc
Pittsburgh, Pennsylvania, United States
University Of Virginia
Charlottesville, Virginia, United States
University Of Washington
Seattle, Washington, United States
Local Institution
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CA186-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.